Business Description
Vaxcyte Inc
NAICS : 541713
SIC : 2834
ISIN : US92243G1085
Share Class Description:
PCVX: Ordinary SharesTotal Employee Number:
507Description
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.94 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -26 | |||||
3-Year EPS without NRI Growth Rate | -22.2 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
3-Year Book Growth Rate | 19.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.83 | |||||
9-Day RSI | 77.67 | |||||
14-Day RSI | 67.44 | |||||
3-1 Month Momentum % | -8.41 | |||||
6-1 Month Momentum % | 6.69 | |||||
12-1 Month Momentum % | 52.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.49 | |||||
Quick Ratio | 7.49 | |||||
Cash Ratio | 7.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.1 | |||||
Shareholder Yield % | -7.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -31.88 | |||||
ROA % | -29.2 | |||||
ROIC % | -71.06 | |||||
3-Year ROIIC % | -53.56 | |||||
ROC (Joel Greenblatt) % | -296.6 | |||||
ROCE % | -35.56 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.78 | |||||
Price-to-Tangible-Book | 2.78 | |||||
EV-to-EBIT | -6.17 | |||||
EV-to-EBITDA | -6.32 | |||||
EV-to-FCF | -8.24 | |||||
| Price-to-Net-Current-Asset-Value | 5.7 | |||||
| Price-to-Net-Cash | 6.01 | |||||
Earnings Yield (Greenblatt) % | -16.21 | |||||
FCF Yield % | -9.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCVX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxcyte Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.88 | ||
| Beta | 1.3201 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 41.54 | ||
| 14-Day RSI | 67.44 | ||
| 14-Day ATR ($) | 2.35488 | ||
| 20-Day SMA ($) | 49.6655 | ||
| 12-1 Month Momentum % | 52.4 | ||
| 52-Week Range ($) | 29.08 - 65 | ||
| Shares Outstanding (Mil) | 144.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxcyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxcyte Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 38 days | ||
| General meeting for 2026 | 2026-06-15 08:30 | 47.46 (+0.34%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 55.64 (-5.73%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 14:15 | 61.75 (+1.31%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-24 16:30 | 60.26 (+3.15%) | ||
| Annual report for 2025 | 2026-02-24 | 60.26 (+3.15%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 60.26 (+3.15%) | ||
| Guggenheim Emerging Outlook: Biotech Summit in New York | 2026-02-12 13:30 | 55.35 (+0.44%) | ||
| Evercore ISI HealthCONx Conference | 2025-12-02 10:20 | 45.52 (+1.20%) |
Show
Entries
Vaxcyte Inc Frequently Asked Questions
What is Vaxcyte Inc(PCVX)'s stock price today?
The current price of PCVX is $57.72. The 52 week high of PCVX is $65.00 and 52 week low is $29.08.
When is next earnings date of Vaxcyte Inc(PCVX)?
The next earnings date of Vaxcyte Inc(PCVX) is 2026-08-06 Est..
Does Vaxcyte Inc(PCVX) pay dividends? If so, how much?
Vaxcyte Inc(PCVX) does not pay dividend.
Guru Commentaries on NAS:PCVX
No articles.
Press Release
Articles on Vaxcyte Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers